Trial Profile
A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Major Depressive Disorder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Oct 2023
Price :
$35
*
At a glance
- Drugs PDC 1421 (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors BioLite Inc
- 09 Oct 2023 According to an ABVC Biopharma media release, company has plans to initiate an End of Phase II (EOP II) meeting with the FDA.
- 28 Feb 2020 According to an American BriVision Corporation media release, A Phase II Part II study is expected to follow at the UCSF Medical Center, along with major medical centers in Taiwan, after and subject to successful completion of this Phase II Part I study.
- 28 Feb 2020 According to an American BriVision Corporation media release, a full clinical study report (CSR) was submitted to the FDA and TFDA on the FDA (on 2019/12/4) and TFDA (on 2019/12/5).